John Edward Noble

US Patent:

55894607, Dec 31, 1996

Filed:

May 4, 1994

Appl. No.:

8/238089

Inventors:

Henry B. Abajian - Hillsdale NJ
John F. Noble - Pomona NY
Joseph J. Hlavka - Tuxedo Park NY

Assignee:

Innapharma, Inc. - Suffern NY

International Classification:

A61K 3804
A61K 3807
C07K 504
C07K 706

US Classification:

514 17

Abstract:

The present invention discloses novel peptides utilized to treat patients suffering from depression. These novel peptides are modifications of the tripeptide hormone MIF, including modification of amino terminus residues, carboxyl terminus residues and internal residues, including addition and substitution of amino acid residues and modification of the peptide bonds and functional side groups of respective amino acid residues. The tri-, tetra-, penta-, and polypeptides of the present invention may be utilized alone or in combination to treat patients suffering from depression.

US Patent:

59104783, Jun 8, 1999

Filed:

Sep 20, 1996

Appl. No.:

8/718270

Inventors:

Joseph J. Hlavka - Tuxedo Park NY
John Fowler Noble - Pomona NY
Henry Baxter Abajian - Hillsdale NJ
Andrew S. Kende - Pittsford NY
Matthew R. Pincus - Brooklyn NY

Assignee:

Innapharma, Inc. - Upper Saddle River NJ

International Classification:

A61K 3800

US Classification:

514 9

Abstract:

The present invention provides peptides, cyclized peptides and peptidomimetics which inhibit the oncogenic and/or transforming activity of the p21 ras protein, pharmaceutical compositions containing at least one of the ras-inhibiting peptides, cyclized peptides and peptidomimetics, and methods for inhibiting the ras-mediated oncogenic and/or transformation process in mammalian cells or tissues.

US Patent:

60937971, Jul 25, 2000

Filed:

Nov 4, 1997

Appl. No.:

8/962962

Inventors:

Henry B. Abajian - Hillsdale NJ
John F. Noble - Pomona NY
Joseph J. Hlavka - Tuxedo Park NY

Assignee:

Innapharma, Inc. - Suffern NY

International Classification:

A61K 3807
A61K 3808
C07K 5107
C07K 706

US Classification:

530329

Abstract:

The present invention discloses novel peptides utilized to treat patients suffering from depression. These novel peptides are modifications of the tripeptide hormone MIF, including modification of amino terminus residues, carboxyl terminus residues and internal residues, including addition and substitution of amino acid residues and modification of the peptide bonds and functional side groups of respective amino acid residues. The tri-, tetra-, penta-, peptides and polypeptides of the present invention may be utilized alone or in combination to treat patients suffering from depression.

US Patent:

57212074, Feb 24, 1998

Filed:

Apr 18, 1995

Appl. No.:

8/424866

Inventors:

John Fowler Noble - Pomona NY
Henry Baxter Abajian - Hillsdale NJ

Assignee:

Innapharma, Inc. - Upper Saddle River NJ

International Classification:

A61K 3800

US Classification:

514 9

Abstract:

An improved method for the treatment of intractable pain is provided by the present invention. The improved method is the intrathecal administration of a therapeutic composition comprising elcatonin and a pharmaceutically acceptable carrier. Intrathecally administered elcatonin produces more potent and prolonged analgesia than elcatonin/calcitonins administered by other routes (e. g. , intravenous, intramuscular injection) and/or opiates administered by different routes (including epidural or intrathecal administration).

US Patent:

58406832, Nov 24, 1998

Filed:

Sep 21, 1995

Appl. No.:

8/531525

Inventors:

Joseph J. Hlavka - Tuxedo Park NY
Matthew R. Pincus - Brooklyn NY
John Fowler Noble - Pomona NY
Henry Baxter Abajian - Hillsdale NJ
Andrew S. Kende - Pittsford NY

Assignee:

Innapharma, Inc. - Upper Saddle River NJ

International Classification:

A61K 3812
C07K 508

US Classification:

514 9

Abstract:

The present invention provides peptides and cyclized peptides which inhibit the oncogenic and/or transforming activity of the p21 ras protein, pharmaceutical compositions containing at least one of the ras-inhibiting peptides, cyclized peptides and peptidomimetics, and methods for inhibiting the ras-mediated oncogenic and/or transformation process in mammalian cells or tissues.

US Patent:

57670838, Jun 16, 1998

Filed:

May 2, 1995

Appl. No.:

8/432651

Inventors:

Henry B. Abajian - Hillsdale NJ
John F. Noble - Pomona NY
Joseph J. Hlavka - Tuxedo Park NY

Assignee:

Innapharma, Inc. - Suffern NY

International Classification:

A61K 3806
A61K 3807
A61K 3808
C07K 706

US Classification:

514 16

Abstract:

The present invention discloses novel peptides utilized to treat patients suffering from depression. These novel peptides are modifications of the tripeptide hormone MIF, including modification of amino terminus residues, carboxyl terminus residues and internal residues, including addition and substitution of amino acid residues and modification of the peptide bonds and functional side groups of respective amino acid residues. The tri-, tetra-, penta-, peptides and polypeptides of the present invention may be utilized alone or in combination to treat patients suffering from depression.